MEK and PI3K inhibition in solid tumors: Rationale and evidence to date

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 3, 2015, Pages 170-180

  Jokinen, E ^a   Koivunen, J P ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Inhibition; MEK; PI3K; Solid tumors; Targeted therapy

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; RAF PROTEIN; RAS PROTEIN;

ARTICLE; CANCER INHIBITION; CANCER THERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 84928743163     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015571111     Document Type: Review

References (71)

1. Adjei A. Cohen R. Franklin W. Morris C. Wilson D. Molina J. et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1 / 2 inhibitor AZD 6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26: 2139–2146.
2. Almoguera C. Shibata D. Forrester K. Martin J. Arnheim N. Perucho M. (1988) Most human carcinomas of the exocrine pancreas contain mutant C-K-Ras genes. Cell 53: 549–554.
3. Barretina J. Taylor B. Banerji S. Ramos A. Lagos-Quintana M. Decarolis P. et al. (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42: 715–721.
4. Baselga J. Campone M. Piccart M. Burris H. 3rd Rugo H. Sahmoud T. et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520–529.
5. Bedard P. Tabernero J. Kurzrock R. Britten C. Stathis A. Perez-Garcia J. et al. (2012) A phase Ib, open-label, multicenter, dose-escalation study of the oral PAN-PI3K inhibitor BKM 120 in combination with the oral MEK1/2 inhibitor GSK 1120212 in patients (pts) with selected advanced solid tumors. J Clin Oncol 30(Suppl.): abstract 3003.
6. Bellmunt J. Teh B. Tortora G. Rosenberg J. (2013) Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol 10: 557–570.
7. Bendell J. Rodon J. Burris H. de Jonge M. Verweij J. Birle D. et al. (2011) Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30: 282–290.
8. Bennouna J. Lang I. Valladares-Ayerbes M. Boer K. Adenis A. Escudero P. et al. (2011) A phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 Inhibitor AZD 6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 29: 1021–1028.
9. Bismar T. Yoshimoto M. Vollmer R. Duan Q. Firszt M. Corcos J. et al. (2011) PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 107: 477–485.
10. Bollag G. Hirth P. Tsai J. Zhang J. Ibrahim P. Cho H. et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596–599.
11. Brachmann S. Hofmann I. Schnell C. Fritsch C. Wee S. Lane H. et al. (2009) Specific apoptosis induction by the dual PI3K/mTOR inhibitor NVP-BEZ235 in HER 2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 106: 22299–22304.
12. Brana I. Siu L. (2012) Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 10: 161.
13. Callahan M. Rampal R. Harding J. Klimek V. Chung Y. Merghoub T. et al. (2012) Progression of RAS-mutant leukemia during raf inhibitor treatment. N Engl J Med 367: 2316–2321.
14. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068.
15. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615.
16. Cancer Genome Atlas Research Network (2012 a) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519–525.
17. Cancer Genome Atlas Network (2012 b) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330–337.
18. Cancer Genome Atlas Network (2012 c) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.
19. Cancer Genome Atlas Research Network (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497: 67–73.
20. Cancer Genome Atlas Research Network (2014 a) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202–209.
21. Cancer Genome Atlas Research Network (2014 b) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507: 315–322.
22. Cancer Genome Atlas Research Network (2014 c) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511: 543–550.
23. Chandarlapaty S. Sawai A. Scaltriti M. Rodrik-Outmezguine V. Grbovic-Huezo O. Serra V. et al. (2010) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58–71.
24. Chapman P. Hauschild A. Robert C. Haanen J. Ascierto P. Larkin J. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.
25. Corcoran R. Cheng K. Hata A. Faber A. Ebi H. Coffee E. et al. (2012) Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23: 121–128.
26. Davies H. Bignell G. Cox C. Stephens P. Edkins S. Clegg S. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
27. Davies M. Fox P. Papadopoulos N. Bedikian A. Hwu W. Lazar A. et al. (2012) Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res 18: 1120–1128.
28. Dienstmann R. Rodon J. Markman B. Tabernero J. (2011) Recent developments in anti-cancer agents targeting PI3K, AKT and mTORC1/2. Recent Pat Anticancer Drug Discov 6: 210–236.
29. Eisen T. Ahmad T. Flaherty K. Gore M. Kaye S. Marais R. et al. (2006) Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95: 58–586.
30. Engelman J. Chen L. Tan X. Crosby K. Guimaraes A. Upadhyay R. et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant KRAS G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351–1356.
31. Engelman J. Luo J. Cantley L. (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606–619.
32. Escudier B. Eisen T. Stadler W. Szczylik C. Oudard S. Siebels M. et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134.
33. Faber A. Coffee E. Costa C. Dastur A. Ebi H. Hata A. et al. (2014) mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-Xl inhibition by suppressing MCL-1. Cancer Discov 4: 42–52.
34. Faber A. Li D. Song Y. Liang M. Yeap B. Bronson R. et al. (2009) Differential Induction of apoptosis in HER 2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 106: 19503–19508.
35. Flaherty K. Infante J. Daud A. Gonzalez R. Kefford R. Sosman J. et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V 600 mutations. N Engl J Med 367: 1694–1703.
36. Gollob J. Wilhelm S. Carter C. Kelley S. (2006) Role of RAF kinase in cancer: therapeutic potential of targeting the RAF/MEK/ERK signal transduction pathway. Semin Oncol 33: 392–406.
37. Hanahan D. Weinberg R. (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674.
38. Hauschild A. Grob J. Demidov L. Jouary T. Gutzmer R. Millward M. et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358–365.
39. Ho A. Grewal R. Leboeuf R. Sherman E. Pfister D. Deandreis D. et al. (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368: 623–632.
40. Hoeflich K. Merchant M. Orr C. Chan J. Den Otter D. Berry L. et al. (2012) Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 Triggers robust apoptosis and tumor growth inhibition. Cancer Res 72: 210–219.
41. Hoeflich K. O'Brien C. Boyd Z. Cavet G. Guerrero S. Jung K. et al. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15: 4649–4664.
42. Hudes G. Carducci M. Tomczak P. Dutcher J. Figlin R. Kapoor A. et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–2281.
43. Infante J. Fecher L. Falchook G. Nallapareddy S. Gordon M. Becerra C. et al. (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13: 773–781.
44. Jokinen E. Laurila N. Koivunen J. (2012) Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. BMC Cancer 12: 612.
45. Juric D. Soria J. Sharma S. Banerjee U. Azaro A. Desai J. et al. (2014) A phase 1b Dose-escalation study of BYL 719 plus binimetinib (MEK162) in patients with selected advanced solid tumors. J Clin Oncol 32:5s (Suppl.): abstract 9051.
46. Kimura E. Nikiforova M. Zhu Z. Knauf J. Nikiforov Y. Fagin J. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454–1457.
47. Lin S. Liu C. Ko S. Chang H. Liu T. Chang K. (2005) Copy number amplification of 3Q26-27 oncogenes in microdissected oral squamous cell carcinoma and oral brushed samples from areca chewers. J Pathol 206: 417–422.
48. Llovet J. Ricci S. Mazzaferro V. Hilgard P. Gane E. Blanc J. et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 37–390.
49. Lorusso P. Shapiro G. Panday S. Kwak E. Jones C. Belvin M. et al. (2012) A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K Inhibitor GDC-0941, in patients with advanced solid tumors. J Clin Oncol 30(Suppl.): abstract 2566.
50. Mendoza M. Er E. Blenis J. (2011) The RAS-Erk and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320–328.
51. Moreno Garcia V. Baird R. Shah K. Basu B. Tunariu N. Blanco M. et al. (2011) A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. J Clin Oncol 29(Suppl.): abstract 3021.
52. Motzer R. Escudier B. Oudard S. Hutson T. Porta C. Bracarda S. et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449–456.
53. O'Reilly K. Rojo F. She Q. Solit D. Mills G. Smith D. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res 66: 1500–1508.
54. Poulikakos P. Zhang C. Bollag G. Shokat K. Rosen N. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427–430.
55. Ramanathan R. von Hoff D. Eskens F. Blumenschein G. Richards D. Renshaw F. et al. (2014) A Phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK Inhibitor refametinib (BAY 86-9766) in patients with advanced cancer. J Clin Oncol 32:5s(Suppl.): abstract 2588.
56. Rinehart J. Adjei A. Lorusso P. Waterhouse D. Hecht J. Natale R. et al. (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22: 4456–4462.
57. Serra V. Scaltriti M. Prudkin L. Eichhorn P. Ibrahim Y. Chandarlapaty S. et al. (2011) PI3K inhibition results in enhanced HER Signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30: 2547–2557.
58. Solit D. Garraway L. Pratilas C. Sawai A. Getz G. Basso A. et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358–362.
59. Sos M. Fischer S. Ullrich R. Peifer M. Heuckmann J. Koker M. et al. (2009) Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 106: 18351–18356.
60. Sousa S. Fernandes P. Ramos M. (2008) Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem 15: 1478–1492.
61. Su F. Viros A. Milagre C. Trunzer K. Bollag G. Spleiss O. et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366: 207–215.
62. Turke A. Song Y. Costa C. Cook R. Arteaga C. Asara J. et al. (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72: 3228–3237.
63. Vasudevan K. Barbie D. Davies M. Rabinovsky R. McNear C. Kim J. et al. (2009) AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16: 21–32.
64. Wallace E. Lyssikatos J. Yeh T. Winkler J. Koch K. (2005) Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem 5: 215–229.
65. Wander S. Hennessy B. Slingerland J. (2011) Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 121: 1231–1241.
66. Weekes C. von Hoff D. Adjei A. Leffingwell D. Eckhardt S. Gore L. et al. (2013) Multicenter phase I trial of the mitogen-activated protein kinase 1 / 2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res 19: 1232–1243.
67. Weigelt B. Warne P. Downward J. (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30: 3222–3233.
68. Wilhelm S. Adnane L. Newell P. Villanueva A. Llovet J. Lynch M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both RAF and VEGF and PDGF Receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129–3140.
69. Yan Y. Serra V. Prudkin L. Scaltriti M. Murli S. Rodriguez O. et al. (2013) Evaluation and clinical analyses of downstream targets of the AKT inhibitor GDC-0068. Clin Cancer Res 19: 6976–6986.
70. Yao J. Shah M. Ito T. Bohas C. Wolin E. van Cutsem E. et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514–523.
71. Zimmer L. Barlesi F. Martinez-Garcia M. Dieras V. Schellens J. Spano J. et al. (2014) Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO 4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin Cancer Res 20: 4251–4261.